They discovered that elevated SNRPA1 contributed to cell invasion and cancer metastasis; blockage of SNRPA1 is a promising synergistic antitumor strategy for sunitinib sensitivity and anti‐PD‐1 immunotherapy. Here, SNRPA1 is linked to cancer.